Invitae (NVTA) Gets a Buy Rating from Oppenheimer

In a report released today, Kevin Degeeter from Oppenheimer maintained a Buy rating on Invitae (NVTAResearch Report), with a price target of $21. The company’s shares opened today at $14.67.

Degeeter observed:

“On 2/12/18, NVTA introduced its noninvasive prenatal screening (NIPS) test for detection of fetal chromosomal abnormalities. Important takeaways from the product launch include:1) in line with our timeline; 2) list price of $2,500 with a $250 patient pay option; and 3) offering improvement in workflow compared to most other NIPS offering by integrating carrier screening into sample collection workflow. We expect NIPS to begin making a meaningful contribution to test volumes in 2Q19 and revenue in 2H19. We expect management to disclose additional details of the launch in the 4Q18 financial results conference call Feb. 19 (4Q18 preview on page 3). Reiterate Outperform, $21 PT.”

According to TipRanks.com, Degeeter is a 4-star analyst with an average return of 14.4% and a 50.0% success rate. Degeeter covers the Healthcare sector, focusing on stocks such as Catalyst Biosciences Inc, Molecular Templates Inc, and Neon Therapeutics Inc.

Invitae has an analyst consensus of Moderate Buy, with a price target consensus of $19.

See today’s analyst top recommended stocks >>

Based on Invitae’s latest earnings release for the quarter ending September 30, the company reported a quarterly GAAP net loss of $31.72 million. In comparison, last year the company had a GAAP net loss of $40.49 million.

Based on the recent corporate insider activity of 28 insiders, corporate insider sentiment is negative on the stock.

TipRanks has tracked 36,000 company insiders and found that a few of them are better than others when it comes to timing their transactions. See which 3 stocks are most likely to make moves following their insider activities.

Invitae Corp. engages in the provision of genetic information into mainstream medical practice. It includes comprehensive panels for hereditary conditions in cancer, cardiology, neurology, pediatric, and rare diseases. The company was founded by Randal W. Scott and Sean E. George on January 13, 2010 and is headuartered in San Francisco, CA.